Samsung Biologics삼성바이오로직스
207940 · KOSPI · ₩SBL · 삼성바이오로직스
₩1,374,000▼ ₩78,000 (5.37%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩4.6T | ₩4.5T | ₩3.7T | ₩3T | ₩1.6T |
| Cost of sales | ₩2T | ₩2.3T | ₩1.9T | ₩1.5T | ₩842B |
| Gross profit | ₩2.5T | ₩2.3T | ₩1.8T | ₩1.5T | ₩726B |
| Operating income | ₩2.1T | ₩1.3T | ₩1.1T | ₩984B | ₩537B |
| Net income | ₩1.8T | ₩1.1T | ₩858B | ₩798B | ₩394B |
| Net income to shareholders | ₩1.8T | ₩1.1T | ₩858B | ₩798B | ₩394B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩11T | ₩17T | ₩16T | ₩17T | ₩8T |
| Current assets | ₩4.4T | ₩5.5T | ₩5.5T | ₩6.5T | ₩2.8T |
| Cash and equivalents | ₩149B | ₩391B | ₩368B | ₩891B | ₩47B |
| Total liabilities | ₩3.6T | ₩6.4T | ₩6.2T | ₩7.6T | ₩3T |
| Current liabilities | ₩2.5T | ₩3.9T | ₩4.2T | ₩4.2T | ₩1.1T |
| Borrowings | ₩919B | ₩1.3T | ₩1.6T | ₩1.1T | ₩160B |
| Total equity | ₩7.5T | ₩11T | ₩9.8T | ₩9T | ₩5T |
| Shareholders' equity | ₩7.5T | ₩11T | ₩9.8T | ₩9T | ₩5T |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩2.2T | ₩1.7T | ₩1.7T | ₩953B | ₩455B |
| Capital spending | ₩1.4T | ₩1.3T | ₩995B | ₩957B | ₩406B |
| Free cash flow | ₩856B | ₩356B | ₩671B | −₩3.8B | ₩48B |
Consolidated where available. Amounts in won.
Also known as: Samsung Biologics / 삼성바이오로직스 / 207940 / KRX:207940
Source: KRX statistical information